Podcasts about cool greg

Wishlist Lost Skies today: https://kindafunny.com/lostskies Wishlist Monaco 2 today: http://kindafunny.com/monaco2 Go to http://rocketmoney.com/kindafunny to cancel your unwanted subscriptions with Rocket Money. Nintendo Switch 2 Pre-orders have been delayed, Tim's review of the Devil May Cry Netflix Show, and Marathon might be ready for a big reveal. Thank you for the support! Run of Show - - Start - Housekeeping Today after, KFGD, you'll get: GAMESCAST - Bless, Rog, and Tim's Nintendo New York trip full recap. After Gamescast there is no Game Showdown. The STREAM is the Return to Verdansk. Today, the map that started it all returns and so do the jabroni boys along with KRIS ANKA! Come watch the boys play Warzone at noon. If you're a Kinda Funny Member: Today's Gregway is XX minutes about XXX. Cool Greg has his very own poster designed by the incredible Panda Musk including some minifig versions of the entire team! The Roper Report  - - Nintendo delays Switch 2 pre-orders because of Trump tariffs - SuperChats - Ad - Devil May Cry on Netflix Review - Bungie's Marathon Finally Emerges From the Shadows to Tease… Something - Miyazaki promises Switch 2 exclusive Duskbloods won't distract FromSoftware from single-player games - Astro Bot Movie Could Be On Its Way as Sony Is ‘Absolutely' Considering an Adaptation - Wee News! - SuperChats & You‘re Wrong Learn more about your ad choices. Visit megaphone.fm/adchoices

Wishlist Lost Skies today: https://kindafunny.com/lostskies Wishlist Monaco 2 today: http://kindafunny.com/monaco2 Go to http://rocketmoney.com/kindafunny to cancel your unwanted subscriptions with Rocket Money. Thank you for the support! Run of Show - - Start - Housekeeping Today after, KFGD, you'll get: GAMESCAST - Andy's Den of Wolves Preview! Then the STREAM is Mike and me Monster Hunting! TOMORROW: Nintendo Switch 2 Direct. 6 am. Cool Greg has his very own poster designed by the incredible Panda Musk including some minifig versions of the entire team! Grab this month's Premium Item before it hits the bricks! Patreon.com/KindaFunny It's been twelve hundred days since we dropped Howard Hospital. Twelve hundred days without Verdansk... This Friday the map that started it all returns and so do the jabroni boys! That's right even ANDY is back to play Call of Duty Warzone one more time. Friday at noon Mike, Nick, Andy and KRIS ANKA IN STUDIO return to the game that brought them all together and also tore them apart for one mega marathon stream of laughter, frustration, and FRIENDSHIP. If you're a Kinda Funny Member: Today's Gregway is 17 minutes about how video games should be revealed and teased AND how YOU should make the podcast you believe in! Thank you to our Patreon Producers: Anatolii Ast, Delaney Twining, Karl Jacobs, & OmegaBuster The Roper Report  - - SWITCH 2 FEVER PITCH IS UPON US - FCC Filing Could Indicate a Possible Upgrade For Nintendo Switch 2 Pro Controller. Eric Van Allen @ IGN - Ad - Switch 2 Games Will Be Focus Of Two Post-Direct Livestreams This Week, Eddie @ GameSpot - Elden Ring Nightreign - Official Ironeye Character Trailer Debuts! - Layoffs at Eidos Montreal, Eddie @ GameSpot - Wee News! - SuperChats & You‘re Wrongs Learn more about your ad choices. Visit megaphone.fm/adchoices

On this week's episode Mel and Aaron talk Aaron's trip to San Francisco, hanging with Cool Greg, being in a Colombian music video, getting a puppy and MORE. All in 20 minutes!

This week, please join author Philipp Lurz and Editorialist Daniel Burkhoff as they discuss the article "Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction" and the editorial "HF?EF: The Mysterious Relationship Between Heart Failure and Ejection Fraction Continues." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: I just cannot wait to tell you about today's feature discussion, Greg. It's about heart failure with preserved ejection fraction and characteristics in the range of that ejection fraction that's above 50%. So, okay. I know, I know. It's like, "Oh my gosh. Wow. How much are we going to be talking about this ejection fraction thing?" But I'm telling you, everybody has to listen to this. It's really a big stride forward in our understanding of these patients with heart failure and a higher ejection fraction. Plus it includes one of my mentors from Mayo Clinic days, and I just can't wait for everyone to hear this. But before we go there, we've got really, really cool original papers in today's issue too. Would you like to start first? Dr. Greg Hundley: You bet Carolyn, and I can't wait for that feature discussion, especially this is a real area of your expertise. So listeners, hold on for that feature discussion. Well, my first paper, Carolyn, really pertains to physical activity. And Carolyn, the study is led by Dr. Don Hoon Lee from the Harvard T.H. Chan School of Public Health. And it evaluated a total of 116,000 adults from two large prospective US cohorts, the Nurse's Health Study and the Health Professional's Follow up Study that took place from 1988 to 2018. And they were examining self-reported leisure time physical activity and assessed the association between long term leisure time physical activity intensity and all cause and cause specific mortality. Dr. Greg Hundley: Now Carolyn, two types of physical activity were assessed. First, moderate physical activity and we're going to abbreviate that as MPA and that was 150 to 300 minutes per week, which is really recommended. Or second, vigorous physical activity for which it's really recommended that one performs 75 to 150 minutes per week. Now, Carolyn, as you know, some individuals accomplish both of these in their routine, some neither, some one or the other. And so it really remains unclear whether higher levels of long term vigorous or moderate are independently or perhaps jointly associated with lower mortality. Dr. Carolyn Lam: Oh, that's so interesting, Greg. Quick, quick, quick, tell us the results. Dr. Greg Hundley: Right Carolyn. So the nearly maximum association with lower mortality overall was achieved by performing approximately 150 to 300 minutes per week of long term leisure time vigorous physical activity or 300 to 600 minutes per week of long term leisure time moderate physical activity or an equivalent combination of both, so mixing those minutes. Also Carolyn, very interestingly, higher levels, suppose you go beyond those limits of either long term leisure time vigorous physical activity of more than 300 minutes per week or moderate physical activity of more than 600 minutes per week did not show clearly further lower all cause cardiovascular disease or non-cardiovascular disease mortality and nor did they show harm. So if you went above those thresholds, you really didn't experience greater harm. Dr. Carolyn Lam: Thanks, Greg. You know I'm going to be trying to apply that. That's so cool. All right. Well the next paper refers to the Cabana Trial, which I'll remind you is a trial in which catheter ablation did not significantly reduce the primary endpoint of death, disabling stroke, serious bleeding or cardiac arrest compared to drug therapy by intention to treat, but did improve quality of life and freedom from atrial fibrillation recurrence. In Cabana, the heart failure subgroup, ablation appeared to improve both survival and quality of life. The current paper led by Dr. Mark and colleagues from Duke Clinical Research Institute looked at the cost effectiveness of this ablation versus angio-rhythmic drug therapy in atrial fibrillation and which was a pre-specified Cabana secondary endpoint. Dr. Greg Hundley: Ah, Carolyn. So what did they find? Dr. Carolyn Lam: Well in this trial based economic evaluation, catheter ablation was estimated to cost $57,893 per QALY or Quality Adjusted Life Year gained compared to drug therapy in the overall cohort. And this was primarily driven by improvement in quality of life. It also cost $54,135 per QALY gained in the heart failure subgroup, driven by both gains in quality of life and survival. In summary, catheter ablation of atrial fibrillation was found to be economically attractive compared to drug therapy in the Cabana trial overall at present benchmarks of healthcare value in the US and based on projected incremental qualities, but not live years alone. Dr. Greg Hundley: Very nice Carolyn. Well, my next paper comes to us from the world of Preclinical Science and it's corresponding author is Dr. Swapnil Sonkusare from University of Virginia School of Medicine. So Carolyn, calcium signals in smooth muscle cells contribute to vascular resistance and control blood pressure. Now increased vascular resistance in hypertension has been attributed to impaired smooth muscle cell calcium signaling mechanisms. And in this regard, transient receptor potential vanilloid four or TRPV4 smooth muscle cell ion channels are crucial calcium entry pathways for smooth muscle cells. However, their role in blood pressure regulation has not been identified. Dr. Carolyn Lam: Wow. TRPV4 smooth muscle cells. Cool Greg. So what did they find? Dr. Greg Hundley: Right, Carolyn. So these authors provide the first evidence that TRPV4 smooth muscle cell channel activity elevates resting blood pressure in normal mice. A1AR stimulation activated TRPV4 smooth muscle cell channels through protein kinase calcium signaling, which contributed significantly to vasoconstriction and blood pressure elevation. Dr. Greg Hundley: Surprisingly, intraluminal pressure induced TRPV4 smooth muscle cell channel activity, opposed vasoconstriction through activation of calcium sensitive potassium channels indicating functionally opposite pools of TRPV4 smooth muscle cell channels. And so Carolyn, this team identified novel smooth muscle cell calcium signaling nano domains that regulate blood pressure and demonstrate impairment in hypertension. Dr. Carolyn Lam: Oh wow, Greg. Thank you so much for that. Well, let's cover the other articles in today's issue. There's a primer by Dr. Jaffe on High Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guidelines for the evaluation and diagnosis of acute chest pain. There's also Research [Letter] in there by Dr. Fordyce on the eligibility for non-invasive testing based on the 2021 American Heart Association and ACC guideline for the evaluation and diagnosis of chest pain, implications from the Promise trial. Dr. Greg Hundley: Great Carolyn. Well, I've also got an exchange of letters to the editor from Professors Benali and Professor Della Bella regarding a previously published article, “Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients with an Implantable Cardioverter Defibrillator, Results from the Multicenter Randomized Partita Trial.” And also there's a very nice Perspective piece from Dr. Udelson entitled “Glucose Insulin Potassium Therapy for Acute Myocardial Infarction, 50 years on and Time for a Relook.” Well, Carolyn, I can't wait to hear more of the discourse between you, the authors and editors on heart failure and preserved ejection fraction. Dr. Carolyn Lam: Yay. Here we go. I'm so excited about today's feature discussion. It's on my favorite topic, heart failure with preserved ejection fraction. Although thanks to one of the authors, Dr. Daniel Burkhoff of the editorial that accompanies it, I don't even know how to pronounce, it's Heart Failure question mark Ejection Fraction. I love it. How would you pronounce that? Dr. Daniel Burkhoff: Yeah, no, we debated how to pronounce it. HFQRef…a question mark? Dr. Carolyn Lam: HFQRef. Oh my goodness. What are we going to come up with next? Dr. Daniel Burkhoff: And we actually thought the editors would have a problem with that. Whenever we put something cute in the title, we always get knocked down. So we haven't yet got knocked down, so we'll see. Dr. Carolyn Lam: No, I'm not knocking you down. Dr. Daniel Burkhoff: But it just really emphasizes that we're in a very confusing time now as it comes to heart failure and ejection fraction, that we have to move on beyond ejection fraction. And although we have these strict buckets and upper and lower limits for each range, that maybe this is in a little bit of a way, doing us a disservice and doing the patients at disservice in terms of treatment. Dr. Carolyn Lam: That's really great. And everybody that was Dr. Daniel Burkhoff from the Cardiovascular Research Foundation in New York. He's the editorialist of today's feature paper. And I'm so excited that we have the corresponding author of today's feature paper as well, Dr. Philipp Lurz from Heart Center Leipzig in Germany. So first, I mean, or second, heartfelt congratulations on this beautiful paper, Philipp. If you could start with telling us all about what you did and what you looked at and what made Dr. Daniel Burkhoff call it now, Heart Failure, QREF? Dr. Philipp Lurz: Yeah. So thank you so much, first of all, obviously for having me for the kind introduction and your kind words about our work. The whole thing started with the observation that in recent drug trials, the response in HFpEF patients to drugs which were before proven to be quite successful in HFrEF actually showed a quite heterogeneous response in HFpEF patients. And that there were some patterns according to the range of ejection fractions. So it seemed that those HFpEF patients with the lower ejection fractions, they respond a little bit better to HFrEF medication than those with a higher ejection fraction. Dr. Philipp Lurz: And HFpEF studies, they included patients within and ejection fraction or 40 and above who normally would probably would consider HFpEF to start with 50 and above. But even in those truly HFpEF patients, so from 50 and anything above to 70, there was a suggestion that there might be differences. 50 to 60 might be something else and then 60 and above. And this is where we started to look into our cohort and to group them according to ejection fraction and see whether we can see some important and clinically meaningful differences in morphology, obviously in function, but then even also in terms of our biopsy results. Dr. Philipp Lurz: And that also implies that we did quite a deep phenotyping of our patients. So we use imaging, echo obviously. We use magnetic resonance imaging. We were able to acquire in a larger percentage of that cohort, by the way, it was 56 patients in total, we were able to get some left ventricular biopsies. And most importantly, when it comes to the functional properties of the left ventricle, we also acquired pressure volume loops. And that has the great advantage that we obviously we can look at low dependent parameters, but more important, also low independent in disease of both systolic and diastolic function. And that's pretty much what we did. Dr. Carolyn Lam: Oh my goodness. I mean, as an editor at Circulation, can I just first tell you that's what really, really stood out? It's the comprehensive, careful, in-depth characterization. It may be 56 patients, but MRI, echo, biopsies, exercise, PV loops. I mean, it was a lot, a lot that you did. Could you boil it down to what you found and maybe just to first clarify to the audience, how did you bend the ejection fraction? And then what you found? Dr. Philipp Lurz: We divided the cohort in two groups. One with an ejection fraction 50 to 60, and the other groups higher than 60% left ventricular ejection fraction. We ended up in lower group, 21 patients, in the higher group with 35 patients. And they were quite different. They had distinct features in terms of morphology, means that the lower injection fraction group, they had larger ventricles. That's probably what you would expect when you group them according to eject fractions. So not that surprising. Dr. Philipp Lurz: And at that point, and they had the same stroke volume. The low ejection fraction group, you could say that they had a certain degree of eccentric modeling, whereas those were the high ejection fraction group, that concentric modeling. When we then looked at the biopsies, the group with the low ejection fraction group, so 50 to 60, they had higher percentage of myocardial fibrosis at 15%. Dr. Philipp Lurz: And then on left ventricular biopsy, we saw that patients with a high ejection fraction group, they had less myocardial fibrosis, so more fibrosis in those with the lower ejection fraction group. And this is really interesting because when we then look at the real size of the pressure volume loop analysis, despite the fact that the high ejection fraction group had less fibrosis, they had the most stiff ventricles on pressure volume loop analysis. So that's already a very important point because it illustrates once again that we should not mistake fibrosis with stiffness, and also not the other way around. There are other parameters which can cause stiffness such as cellular stiffness, and it's not just the extracellular matrix. Dr. Philipp Lurz: So that's an important point. Those patients with high ejection fraction, they had the most stiff ventricles. They had the most relevant limitations in left ventricular filling, so the most marked diastolic dysfunction. We also looked at systolic parameters and there we found that they had a very high contractility. So this is the end systolic pressure volume relationship or also called elastics and that's a marker for contractility. So these ventricles with high ejection fraction, they can contract very well. They have high contractivity. But this is also a marker of systolic stiffness. So they stiff, both in terms of diastolic properties, but also systolic properties. And there, their most important limitation is the limitation in filling. Dr. Philipp Lurz: The other group, injection fraction 50 to 60, they do have some stiffness. Obviously we are talking about HFpEF. This is a disease of a diastolic dysfunction. So they have increased stiffness, but to a lesser extent. They can feel a little bit better, but what we see there is a reduction in contractility, so systolic properties. So you could argue that in some extent, that group 50 to 60, they behave a little bit more like HFrEF. Whereas those with high ejection fraction, they're completely different. Very stiff, both doing diastolically and sistolly. Dr. Carolyn Lam: Thank you so much. Now I really have to get the gurus insight into this. And of course by guru, I mean, Dr. Daniel Burkhoff. First, I'm going to take this opportunity to share a little private personal story that it's very hard for me to call Dr. Burkhoff, "Dan", although if you will allow me it's because I was a fellow when I first met Dr. Burkhoff. And one of my first papers was actually communicating with Dr. Burkhoff trying to draw these PV loops based on the noninvasive measurements that I was obtaining at the Mayo Clinic in the Olmsted County Cohort. And so this is just really making me smile. So Dan, if I may, what do you make of all this? And if you could give us what you think may be the clinical take home message. Dr. Daniel Burkhoff: Thank you so much, Carolyn. And also again, Philipp, congratulations on really a really important paper. I think as Carolyn was saying, one of the many things that impressed me was the multifaceted aspects of the thorough evaluation using multi modality characterization, which is in my mind, unprecedented, especially for this particular group of patients. And you summarized the main results very well. But to me, the thing that really struck me and that we really tried to emphasize in our editorial was the differential response to exercise, to hand grip exercise in this point. Dr. Daniel Burkhoff: As you already said, and I don't think this could be understated, that in the lower range, the 50 to 60, these patients were able to fill, the ventricle was able to fill more, the end diastolic pressure still went up significantly into an abnormal range, which is of course is one of the requirements for the diagnosis of HFpEF. But those patients, the end diastolic volume was able to increase and that helped them to increase their cardiac output. Dr. Daniel Burkhoff: In the higher EF group, the greater than 60, the end diastolic pressure went up, but the volume did not increase. So the end diastolic pressure volume relationship became higher elevated. And this of course, was reminiscent of what was identified in the early nineties by Dalane Kitzman. And really, he didn't make this distinction between the lower half and the higher half. And we had also in a paper that we did with David K and others, seen a similar finding a couple years ago. And I think this is really, to me, was the along with the apparently disparate findings on myocardial biopsies with fibrosis going the wrong way, if you will, as you already commented on. So this is at least for the higher EF group, is identifying what I would refer to as really true diastolic dysfunction. Dr. Daniel Burkhoff: That means that the patients can't fill, there really is some problem why the EDP can go up, but the volume does not increase. And this is obviously for future research, we have to understand what is the difference between these two groups. There are several speculations about why it might. For example, one thing that has been proposed in the literature is the pericardial restraints. If the heart is constrained in a tight pericardium, the volume is recruited from the venous system, which is another what I think is a very important part of this HFpEF phenotype, but the heart is already constrained. That would elevate both the CVP and the wedge pressure without concomitant increases in RV or LV volumes, and therefore limit the ability to increase the cardiac output. Dr. Daniel Burkhoff: Another alternative is delayed relaxation. That means a true abnormality of active relaxation. The tau if you will, but I believe in your study, if I remember correctly, the tau was not that abnormal and did not really change very much in either group. So it was harder to really pin it on an abnormality of active relaxation. So that was one really, I think, really important finding. Dr. Daniel Burkhoff: The second is now in the group 50 to 60 where they could fill, one of the limitations of the study that you pointed out was that there's no control group. So why this population, this HFpEF population, the EDP increased, but the EDV the end diastolic volume also increased, so what's different between those patients and normals? That we don't really have an answer for yet. So that would be one thing is to compliment these findings with results in a true control group that does not have HFpEF. Dr. Daniel Burkhoff: So we still have this mystery of why does EDP go up in this group? My perspective is not an abnormality of diastolly. It's not a diastolic dysfunction, even though it's a HFpEF. I've been trying to promote this idea for more than 20 years, that all HFpEF is not an abnormality of diastolic ventricular properties. There may be extra cardiac factors even beyond the pericardium in this group. So I think these results are just further telling us how complicated and individualized our approach to the pathophysiology of these patients should be. Dr. Daniel Burkhoff: And also just one final comment, making a strict cutoff at 60% or 57% as we saw from Valsartan Cuba trial, Valsartan study, is clearly also not going to do us justice. Let's say that we're dealing with anyway, patients with two different pathophysiologies. There's going to be a distribution of these different mechanisms and there's going to be an overlap of these distributions. So we need to start thinking about how we individualize and characterize the pathophysiology in individual patients. So maybe patients with EF of 55, certain patients with EF 55 will not respond to Sacubitril- Valsartan and maybe some patients with an EF of 62 will. So we need to go more deep into the clinical characterization. Dr. Daniel Burkhoff: And methods that you use in particular, the pressure volume loop, seem to separate, very nicely, these two different, at least two different subtypes. So I think it's very exciting, and I think people should really take notice of what you found and build on this as a foundation and understand that we need to go deeper on the clinical side to phenotype these patients. Dr. Carolyn Lam: Philip, what are your thoughts? Dr. Philipp Lurz: No, I think that the concept about stress and unstressed volume is extremely important and fascinating, but that's where it gets really complex because you could make the conclusion from our results that especially the high ejection fraction group, they are have a very high preload sensibility, which means that when we reduce pre-load too much in them, they drop the stroke volume very suddenly. So that's probably also the clinical question for the future. There are many patients, HFpEF patients in whom we should reduce stress volume and they can benefit from that. Dr. Philipp Lurz: But I also believe that there is a cord of patients, and those are probably more those with high ejection fraction. They actually, they could experience some harm if you reduce preload too much because of the severe filling restrictions, because of the inability to increase end diastolic volumes, especially as an adaptation to exercise. And I think if we find out ways to differentiate who will benefit from preload reduction and from decongestion and who actually might experience even harm from these interventions, then we are certainly one step further. Dr. Carolyn Lam: If I may, I just, I could go on forever, but I know that there's going to be this question that the audience is immediately thinking. Here we are going into the weeds, hemodynamics, we all love it. In fact, I think we're all kind of a little bit geeky about it, but then you've got, Emperor preserved, the Deliver Trial sort of being positive in heart failure with ejection fraction above 40. So, do we really need to understand the different hemodynamic? What do you think is happening that this sort of blanket benefit can occur? Dr. Philipp Lurz: I don't think that everyone will benefit. And I think that a better understanding of the underlying pathophysiology will help to even increase the rate of responders and dissect of those who will not respond or we need a different therapy. Obviously here we group patients according to ejection fraction. We just discussed that this is a very rough way to characterize patients. So the next step certainly would be to understand or to see distinct patterns in left ventricular functional behavior irrespective of ejection fraction. Because you might can skip ejection fraction at one day, but the conclusion is not, at least not in my opinion, that all heart failure is the same. Dr. Carolyn Lam: Nice. And Dan, what do you think? Dr. Daniel Burkhoff: Well, I think with STLT2 inhibitors, first of all, we're looking forward to actually seeing the results from Deliver what the details of it in terms of mortality versus hospitalizations and quality of life. But with regard to HSGL2 inhibitors, I don't think we know the mechanism. I mean, I've read about six papers that definitively talk about different mechanisms of action. I think we don't know. And even despite, let's say positive studies, there's still a significant residual risk that these patients have. So these are not the end of the story by any means. I think this is the beginning of the story and there's still going to be a lot to learn. Dr. Daniel Burkhoff: I think with SGLT2 inhibitors, I think it's difficult to identify who is or how do you define a responder on an individual patient basis? When we look at groups and you look at mortality and hospitalizations, yes, you can identify them. But that group does not overlap exactly with those who have an improvement in quality of life. So I think that we're just at the beginning, Dr. Daniel Burkhoff: I do think that a deeper phenotyping is going to be the way to go ultimately and I think we're going to need more therapies. Thanks again, Carolyn for inviting me to do the editorial and to participate in this. And I would really be remiss if I did not mention the extraordinary contributions for Mickey Brener and also Barry Borlaug who were equal contributors to this editorial and the evaluation of this paper. So I'm really indebted to both of them for this interpretations. And thank you again, Philipp, for just a wonderful paper. Dr. Carolyn Lam: Couldn't have said it better and I just want to thank you once again for providing that deeper phenotyping for opening the door. Many of us said it again and again, this is the beginning and we need more studies, frankly, in yours. I mean, I think Dr. Burkhoff wants you to send normal, healthy people for MRI biopsies, exercise, echo. I'm kidding, on PV loops, but it's true. We need that data. We need the same and the HFrEF and really just to understand the whole thing. I'm so excited about what this paper opens up. Dr. Carolyn Lam: I am thrilled to see your editorial, Dan. I'm sure it's going to be well received. Everyone who's listening to this, Pick up the paper, pick up the editorial. Thank you so much for joining us today. You've been listening to Circulation on the Run and from Greg and I, don't forget to tune in again next week, Dr. Greg Hundley: This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit hajournals.org.

In this episode Jessi discusses the recent legislation introduced in Texas targeting the parents/guardians of trans youth and the (intentional?) misconceptions around the gender affirming medical care that will be denied to those who need it, and the vilification of those who support access to those services. The Avatars Project: https://jessikneeland.com/products/the-avatars-project/Intro to the 4 Body Image Avatars: https://youtu.be/SsxQ9qO0-a4Get my full Body Image Avatar Guide here: https://jessikneeland.com/products/av...Find more resources here: https://jessikneeland.com/Instagram: https://www.instagram.com/jessikneeland/

For RTX 2020 we had Greg, Tim, Nick, Kevin, Joey, Andy, Barrett, and Blessing all on at once and it is chaos. (Cool Greg didn't want to be on camera.)

How did we convince Cool Greg to be on this podcast? Even we don't know. This week Aaron, Evan, Flurpl, and very special guest Cool Greg from Kinda Funny come together to talk about drugs, quarantine, and Aaron's weird eating habits. For more ScootGang content check us out at https://twitter.com/scootgangtweets and https://www.youtube.com/channel/UCRAV7xwfk8j2iycE5zjkH1Q ScootGang Discord: https://discord.gg/zbf9YYA Aaron’s Twitter: https://twitter.com/aaron_moeller Flurpl’s Twitter: https://twitter.com/meyerbw Evan’s Twitter: https://twitter.com/thatevanjordan Cool Greg's Twitter: https://twitter.com/KindaCoolGreg

Logan sits down with Cool Greg from Kinda Funny to talk about wrestling, MegaRan, Sasha Banks, and how he came to work for KF! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Logan sits down with Cool Greg from Kinda Funny to talk about MegaRan, Wrestling, Sasha Banks, and Orange is the New Black!

Hurry to upstart.com/KINDAFUNNY to find out HOW LOW your Upstart rate is. Pick up TROJAN condoms at www.amazon.com/TrojanCondoms or wherever you get your condoms! Get 10% off all Logitech G products with promo code KINDA at logitechg.com. Andy, Joey, and Cool Greg talk about what everyone's My Hero Acadamia quirks would be, common things we've never done, and pets we want to have.

Welcome to the very first episode of Knight Light! We sit down with Kinda Funny's Cool Greg to talk about horror and genre movies, his favorite horror icon, and why he enjoys horror. Follow Cool Greg @kindacoolgreg (https://twitter.com/kindacoolgreg) For the next episode, we are discussing and breaking down Ti West's The House of the Devil (https://www.youtube.com/watch?v=oM3NAtGR2qc) .  ————————————————————— Like what you hear? Feel free to subscribe and rate us 5-stars on your favorite podcast service. Know someone that would like this podcast? Please share and help us grow! Want to be a part of the growth of GoodKnight Life? Support us at these links! WEBSITE: http://www.goodknight.life PATREON: http://patreon.com/goodknightlife TWITTER: http://twitter.com/goodknightlife

Go to https://Patreon.com/KindaFunny to start watching WWE In Review today! Cool Greg goes one on one against WWE Superstar Sasha Banks. https://twitter.com/SashaBanksWWE

Get 20% off and free shipping with the code MORNING at http://Manscaped.com. Get started with the Hims complete hair kit for just $5 today by going to http://forhims.com/KFMS. Tim and Cool Greg sit down with the always amazing Mega Ran to talk video games, rap music, and wrestling. https://twitter.com/MegaRan

Get started with the Hims complete hair kit for just $5 today right now at http://forhims.com/KFMS. 25% off your first order of the best seller variety pack at http://RXbar.com/kindafunny, promo code kindafunny. This episode we talk about straws and bath water. Time Stamps - 00:04:40 - Let’s Go For A Scroll Housekeeping 00:09:30 - In Other News 00:20:40 - We Wants To Show You Stuff 00:34:49 - RX Bars 00:37:05 - Hims 00:39:35 - Facebook Algorithm T-Shirts 00:40:42 - Clickbait 00:45:00 - #FunClipz (Brought to you by Patreon.com/KindaFunny) 00:53:25 - Chat Room

Get 15% off your first pair at http://meundies.com/morning Get $30 off 23andMe’s Health + Ancestry Kit at http://23andme.com/games Is the Cool Greg bot more Cool Greg than Cool Greg?

Get your first refill pack free at http://getquip.com/kfms Start your 30-day trial at http://audible.com/kf or text KF to 500-500. Tim and Nick discover secrets about Andy and Rahul, do a 5 minute music challenge, and continue to be mystified by Cool Greg. Time Stamps - 00:03:00 - Let’s Go For A Scroll Housekeeping 00:08:20 - In Other News 00:11:52 - bougie - Word of the Day 00:14:42 - Tim Wants To Show Nick Stuff 00:28:10 - Nick Wants To Show Tim Stuff 00:35:14 - Tim Wants To Show You Stuff 00:38:40 - Quip 00:40:22 - Audible 00:42:00 - The Cool Greg Effect 00:49:45 - Clickbait 00:53:00 - Facebook Algorithm Shirts 00:55:00 - #FunClipz (Brought to you by Patreon.com/KindaFunny)

Get 3 months of wireless for $20, and get the plan shipped to your door for FREE, by going to http://mintmobile.com/morning Tim and Nick try to understand how Cool Greg's mind works. Time Stamps - 00:06:15 - Let’s Go For A Scroll Housekeeping 00:10:27 - In Other News 00:13:45 - Tim Wants To Show Nick Stuff - https://www.reddit.com/r/kindafunny/comments/anle8z/the_kinda_funny_original_best_friend_soundtrack/ 00:32:18 - Mint Mobile 00:34:20 - Tim Wants To Show You Stuff 00:37:38 - Facebook Algorithm T-Shirts 00:39:20 - Cool Greg Tweetz 00:46:39 - Clickbait 00:52:40 - You want to show us stuff - #FunClipz (Brought to you by Patreon.com/KindaFunny) - https://www.youtube.com/user/TheCybertronicSpree 01:01:32 - Word of the Day - Contronym 01:02:40 - Chat Room

Join Blessing as he has on special guests: Cool Greg Gettys, Emmett Watkins Jr., and John Haze to discuss their favorite albums of last year. Super Throne Watch is a monthly podcast only on okbeast.com. Over here we discuss hip-hop music and talk about what’s going on in the culture. If you like that, subscribe […] The post Our Favorite Albums of 2018 (Feat. Cool Greg Gettys of Kinda Funny) – Super Throne Watch Ep. 19 appeared first on OK Beast.

Get $100 off the Eero base unit and 2 beacons package, and 1 year of Eero Plus http://eero.com/kindafunny and enter kindafunny at checkout. Tim and Nick find out how sick you all actually are. Time Stamps - 00:06:12 - Housekeeping 00:10:05 - In other news segment - "you've another think coming" 00:15:30 - Cool Greg's tweet to Trump 00:18:00 - Police seize illegal alligator from New York state home 00:20:08 - Man tried to sneak snake onto plane in his pants 00:22:00 - Women twerk atop moving vehicle on missouri highway 00:24:15 - Mina Kimes "Go for it Andy" 00:26:25 - 186 days till Hobbs & Shaw 00:27:45 - Tim wants to show Nick stuff segment 00:34:20 - Tim wants to show you stuff segment: MegaRans 2018 in gaming recap song 00:35:00 - Sweet Nasty Love segment 00:37:30 - Click Bait 00:41:45 - Facebook algorhythem shirt 00:42:30 - Eero Wifi 00:44:00 - The Great Firewall of Kevin (Funclips) 00:57:30 - Word of the day 00:58:00 - Top 10 Pornhub searches of 2018 01:09:40 - The Chatroom

Don't wait! Go to http://stamps.com and enter: morningshow Joey and Greg react to the new Men In Black: International trailer, talk about To All The Boys I've Loved Before sequel, and worry about a cobra. -To All the Boys Sequel video (23:55 mins) -Men in Black international trailer has dropped (32:58 mins) -The weird things Cool Greg has seen (40:15 mins) -Elon Musk's futuristic tunnel transit system (42:10 mins) -The story behind yesterdays big topic (47:22 mins

Get 15% off your Loot Crate subscription at http://lootcrate.com/KFMS with promo code: KFMS. Get 15% off your first pair of MeUndies at http://meundies.com/morning Nick and Tim talk Bumblebee, and watch the last trailer for Fantastic Beasts 2 with the one-and-only Cool Greg. Time Stamps - -Fantastic Beasts trailer (30:16 mins) -Disney plans to use James Gunn’s guardians 3 script, confirms Sean Gunn (43:44 mins) Thanks to https://www.twitter.com/kumailh for our timestamps!

Get 15% off your first pair at http://meundies.com/morning Joey and Andy talk about the new iPhone rumors, the final Predator trailer, and get Cool Greg's opinion on the new Eminem track for Venom. -This is iPhone XS - design, larger, version and gold colors confirmed (9:53 mins) -Feast your eyes on the Pixel 3 XL (13:44 mins) -Final Predator Trailer (19:01 mins) -Stephen King's IT: Chapter 2 how the time jump will work, new cast explained and more (23:19 mins) -Dinosaur Toys (32:05 mins) -Eminem and Venom, Together at last (35:55 mins) -New segment: Internet of the week (42:11 mins) Thanks to twitter.com/kumailh for our timestamps!

Thanks to Simple Contacts.. Save $20 on your first Simple Contacts order at http://www.simplecontacts.com/kindafunny20 and use promo code: kindafunny20. Andy, Nick, Jared and Cool Greg are HYPED for the new Fantastic Beasts trailer. We also talk about Mission Impossible: Fallout, Jackie Chan, and Andy getting to play Spider-man without Nick.

Thanks to Hims for sponsoring this episode. Get a trial month for $5 at http://forhims.com/morningshow Thanks to MeUndies for sponsoring this episode. Get 20% off your first pair at http://meundies.com/morning Tim and Nick talk about Incredibles 2, Oceans 8, the newly formed Space Force, and the crazy story of Cool Greg getting kicked off of an Alaska Airlines flight!

Nick and Andy (and Cool Greg) talk about the new trailer for Fantastic Beasts: The Crimes of Grindelwald, Nicholas Cage as Superman, 15 Second of Sports, and which video game should Nick master. Time Codes - -New fantastic beasts trailer (23:01 mins) -The irishman could be scorseses most expensive film yet (32:28 mins) -Margot Robbie now in negotiations to play sharon ate in quentin tarantino film (35:36 mins) -Nicolas Cage will finally play superman (36:19 mins)

Cool Greg and Tim celebrate Valentine's day the only way they know how. -Rita Ora joins Ryan Reynolds in Pokemon movie 'Detective Pikachu' (8:49 mins) -Ready Player One poster (11:00 mins) -I Kill Giants poster & trailer (14:00 mins) -Batman Ninja English trailer (19:35 mins) -Han Solo toys & Star Wars lego (23:30 mins) -Incredibles 2 posters (27:15 mins) -LeBron James to throw new house party with updated version of a classic movie (23:07 mins) Thanks to http://www.twitter.com/kumailh for our timestamps!

Yo what’s up!? Super Throne Watch is here with our first episode featuring Cool Greg Gettys of Kinda Funny. Blessing, Roger Pokorny (Rogformer), and Cool Greg sit down to break down our history with hip-hop, our top fives, and our in depth breakdown of the rap albums of 2017. Super Throne Watch is a monthly […] The post 2017 Rap Music in Review (Feat. Cool Greg Gettys of Kinda Funny) – Super Throne Watch Ep. 1 appeared first on OK Beast.

Mega64's Rocco Botte joins Nick to talk about Black Panther, Ant-Man’s new villain, and finally answer the question, “just where are the cookies at”? -Cool Greg on 2017 rap music in review (24:40 mins) -Black Panther sets Alamo Drafthouse superhero record (25:40 mins) -Ant man and the wasp: who is the ghost (28:25 mins) -Tommy Wiseau has officially annoinced a 3D version of The Room (32:50 mins) -Purge 4 new title and poster revealed (36:50 mins) -Man can name his son Goku if he can get 1 million likes (39:50 mins) Thanks to http://www.twitter.com/kumailh for our timestamps!

Tim Gettys joins Nick today to talk Venom movie news, Ivan Drago’s son get’s cast for Creed 2, John Carpenter may or may not be dead, and Apple has way too much money. -The Cool Greg effect - Lil Uzi Vert story (17 mins) -Venom: New Image confirms movies villians (20:17 mins) -Creed 2 have casted Big Nasty (26:12 mins) -John Carpenter assures fans hes alive after errant tweet (31:45 mins) -Apple just put the finishing touches on its new $5 billion headquarters (34:38 mins) Thanks to twitter.com/kumailh for our timestamps!

For the final AMA, Cool Greg interviews Greg Miller. Let's see what happens, fam!